Severe mental illness research

Our aim is to increase our understanding of the biology and treatment of severe mental illness with focus on schizophrenia, bipolar disorder, melancholic depression and catatonia

Our research projects encompass clinical studies as well as national register-based studies. In our clinical studies we investigate effect and mechanisms of different brain stimulation treatments for severe mental illness: Electroconvulsive treatment (ECT) and repetitive transcranial magnetic stimulation (rTMS). The assessments covers cognitive function, brain imaging with magnetic resonance imaging (MRI), positron emission tomography (PET) as well as different neurophysiology assessments of cortical excitability, frontal lobe hemodynamics, electroencephalographic deviance detection, autonomic nervous system regulation and biochemistry of the neurotransmitter systems in blood and cerebrospinal fluid. Further, an ongoing project evaluates brainstem evoked response audiometry as a diagnostic tool in schizophrenia and ADHD.

Severe mental illness, metabolic syndrome and mortality is another research track. We investigate differences in the care of metabolic syndrome related morbidity in patients with and without schizophrenia or bipolar disorder, from myocardial infarction care to bariatric surgery.

We also have several pharmacoepidemiology projects using the Swedish Prescribed Drugs Register, along with other registers such as health care quality registers. In these cohorts we study adherence to drug treatment and outcome in severe mental illness and the safety and effectiveness of psychotropic drug use.

Group members:

Robert Bodén
Johan Bengtsson
Eric Clapham
Janet Cunningham
Lisa Ekselius
Eva Lindström
Leif Lindström
Björn Milesson-Fors
Björn Nilsson
Jonas Persson
Elin Thörnblom
Johan Lundgren
Lovisa Malabeux

Contact

Project leader:

Robert Bodén

E-mail: robert.boden@neuro.uu.se

Rekrytering av patienter till behandlingsstudien MASCHDEP pågår